- Trial phase
- Approved
- Time to market
- Already approved and launched in the US and Mexico (Q3 2026) and EU (Q2 2026). Commercial availability is underway.
- Why 3/10
- The Fostera PRRS Needle-free microdose was already approved in the US and Mexico during Q3 2026 (announced November 5, 2026). No further binary regulatory catalysts remain for this specific product. For a diversified company like Zoetis, this is a minor product line extension, not a make-or-break event.
The Fostera PRRS Needle-free microdose has already been approved in the US and Mexico (Q3 2026) and in the EU as Suvaxyn PRRS Needle-Free Microdose (Q2 2026). No further binary regulatory catalysts remain for this specific product. Watch for commercial adoption metrics in Zoetis's livestock segment in future quarterly reports, but this is a minor product line extension within a diversified portfolio.
Price Chart
Executive Summary
Fostera PRRS Needle-free microdose is a new needle-free delivery format of Zoetis's existing modified-live virus vaccine that protects pigs against porcine reproductive and respiratory syndrome (PRRS). It was approved in the US and Mexico during Q3 2026, following EU approval of the related Suvaxyn PRRS Needle-Free Microdose in Q2 2026. For Zoetis (NYSE: ZTS), a diversified animal health giant with ~$9.3B in annual revenue, this is a minor product line extension within its livestock segment. The approval is already a past event with no remaining binary catalyst, and the stock's performance will continue to be driven by broader portfolio dynamics, competitive pressures in companion animal products, and overall livestock market conditions.
How It Works
Fostera PRRS is a modified-live virus vaccine that protects pigs against porcine reproductive and respiratory syndrome (PRRS), a viral disease that causes reproductive failure in sows and respiratory illness in young pigs. The 'Needle-free microdose' version delivers the same vaccine through a needle-free intramuscular injection device, using a smaller dose volume. This reduces labor, eliminates needle-stick injury risk for workers, and causes less stress to the animals compared to traditional needle injection.
Trial Status
The Fostera PRRS vaccine (original formulation) has been commercially available for years. The Needle-free microdose version received regulatory approvals in the EU (Q2 2026 as Suvaxyn PRRS Needle-Free Microdose), and in the US and Mexico (Q3 2026 as Fostera PRRS Needle-free microdose). No clinical trials are pending.
The Two-Sided Case
Upcoming Catalysts
- No further binary regulatory catalysts for this specific product. Commercial adoption and revenue contribution will be reflected in Zoetis's quarterly livestock segment results.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zoetis Inc. 8-K ZTS ·Originating report